Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis

Journal of Dermatological Treatment

Volumn 26, Issue 3, 2015, Pages 235-239

  Viswanathan, Hema N ^a   Chau, Dina ^a   Milmont, Cassandra E ^a   Yang, Wenjjing ^a   Erondu, Ngozi ^a   Revicki, Dennis A ^b   Klekotka, Paul ^a  

^a AMGEN INC   (United States)

^b EVIDERA   (United States)

Author keywords

Brodalumab; Dermatology life quality index; Health related quality of life; Patient reported outcomes; Plaque psoriasis; Psoriasis area and severity index; Psoriasis symptom inventory; Static physician global assessment

Indexed keywords

BRODALUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SKIN EXAMINATION; SKIN REDNESS; STATIC PHYSICIAN GLOBAL ASSESSMENT; SYMPTOMATOLOGY; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SKIN;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PRURITUS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84937898960     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2014.943687     Document Type: Article

References (14)

1. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140-7.
2. Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005;53: 887-9.
3. Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216:260-70.
4. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25-31.
5. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238-44.
6. Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo. 2007;59:64-7.
7. Shikiar R, Bresnahan BW, Stone SP, et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53.
8. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
9. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-16.
10. Martin ML, McCarrier KP, Chiou CF, et al. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013;24:255-60.
11. Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013;24:356-60.
12. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366:1181-9.
13. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659-64.
14. Dommasch ED, Shin DB, Troxel AB, et al. Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol. 2010;162:835-42.